Pancreatic cancer drug may hold promise for lung cancer as well, early study suggests
Summary
A new drug called daraxonrasib, already approved for advanced pancreatic cancer, has shown early signs of reducing tumors in about one-third of lung cancer patients with specific mutations. In an early study, the drug was given to 136 lung cancer patients who had not responded well to other treatments, and it was generally safe but caused some side effects.Key Facts
- Daraxonrasib is a pill recently approved to treat advanced pancreatic cancer.
- It was tested in 136 patients with non-small cell lung cancer who have mutations in RAS proteins.
- About 31% to 37% of patients, depending on the dose, saw their tumors shrink after treatment.
- Most patients experienced side effects; 54% had severe side effects like rash, diarrhea, nausea, and inflammation in the mouth or digestive tract.
- Lung cancer is a leading cause of cancer death and affects about 230,000 people annually in the U.S.
- The FDA will likely require larger late-stage trials before deciding if daraxonrasib can be approved for lung cancer treatment.
- Daraxonrasib was granted a "Breakthrough Therapy" designation for pancreatic cancer, speeding up its development and review.
- The drug is sold under the brand name Rasonque by Revolution Medicines, the company that funded the study.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
